Company Overview and News

 
Pestech earnings growth story seen as positive

2018-10-11 theedgemarkets
Pestech International Bhd (Oct 10, RM1.42) Maintain outperform with an unchanged target price (TP) of RM1.95: Pestech International Bhd announced on Tuesday that the Ansaldo STS Pestech Consortium, an unincorporated consortium between Pestech’s wholly-owned subsidiary Pestech Technology Sdn Bhd and Ansaldo STS Malaysia Sdn Bhd, had accepted a letter of award from Syarikat Pembinaan Yeoh Tiong Lay Sdn Bhd, under the SIPP-YTL joint venture for the turnkey EPC (engineering, procurement and construction) relating to the signalling system for the Gemas-Johor Baru electrification double-track at a fixed subcontract price of RM339 million.
5219

 
Pestech bags RM75mil rail job

2018-10-09 thestar.com.my
KUALA LUMPUR: A consortium, in which Pestech International Bhd is a partner, has secured the signalling systems contract for the Gemas-Johor Baru electrified double track project.
5219 BSMAF 1818

 
Pestech gets RM75m job for Gemas-JB electrified double-track project

2018-10-09 theedgemarkets
KUALA LUMPUR (Oct 9): Pestech International Bhd secured a sub-contract signalling system works worth RM75 million for the electrified double-track project from Gemas to Johor Bahru.
5219 BSMAF 1818

 
KLCI remains in the red, tracks regional slump

2018-10-04 theedgemarkets
KUALA LUMPUR (Oct 4): The FBM KLCI retreated at the midday break, in line with slump at most regional markets.
HLFBF 5183 PECGF 1082 BATS 4162 7765 5014 9334 7123 5199 4588 3026 0026 5219 MYPRY HIPEF

 
Pestech wins RM399m subcontract for Gemas-JB rail track

2018-09-26 theedgemarkets
KUALA LUMPUR: Pestech International Bhd has bagged a RM399 million subcontract from Syarikat Pembenaan Yeoh Tiong Lay Sdn Bhd to undertake engineering, procurement, construction and maintenance works relating to the electrification system for the electrified double track from Gemas to Johor Baru.
5219 BSMAF 1818

 
Pestech rises 5.52% on bagging RM399 million sub-contract

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): Pestech International Bhd shares rose 5.52% this morning after it bagged a RM399 million sub-contract from Syarikat Pembenaan Yeoh Tiong Lay Sdn Bhd to undertake engineering, procurement, construction and maintenance works relating to the electrification system for the electrified double track from Gemas to Johor Baru.
5219

 
Pestech gets RM399mil sub-contract job in Johor

2018-09-26 thestar.com.my
In a filing with Bursa Malaysia yesterday, Pectech said it had received a letter of award from Syarikat Pembenaan Yeoh Tiong Lay Sdn Bhd (YTL), under a consortium between SIPP Rail Sdn Bhd and YTL joint venture. It said the contract is related to the electrification system for the electrified double track from Gemas to Johor Baru.
5219 BSMAF 1818

 
KLCI seen extending consolidation, firm crude oil price to offer respite

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI is expected to continue its consolidation phase and hover below the 1,800-point level but may find some respite from high crude oil prices.
1201 5016 6556 7668 5219 4405 6874 2143 5189

 
KLCI seen extending consolidation, firm crude oil to offer respite

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI is expected to continue its consolidation phase and hover below the 1,800-point level but may find some respite from high crude oil prices.
1201 5016 6556 7668 5219 4405 6874 2143 5189

 
Sapura Energy, ECM Libra, Hai-O, Velesto, Maxwell, Deleum, Pestech, OpenSys, Sumatec, KUB, V.S. Industry, Ann Joo, Maybulk, Tan Chong Motor and Warisan TC Holdings

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): Based on corporate announcements and news flow today, companies in focus on Wednesday (Sept 26) may include: Sapura Energy Bhd, ECM Libra Financial Group Bhd, Hai-O Enterprise Bhd, Velesto Energy Bhd, Maxwell International Holdings Bhd, Deleum Bhd, Pestech International Bhd, OpenSys (M) Bhd, Sumatec Resources Bhd, KUB Malaysia Bhd, V.S. Industry Bhd, Ann Joo Resources Bhd, Malayan Bulk Carriers Bhd (Maybulk), Tan Chong Motor Holdings Bhd and Warisan TC Holdings Bhd
PBLOF 6874 1295 2143 5189 1201 5016 6556 7668 5219 4405 BSMAF 1818

 
Pestech bags RM399m subcontract works for Gemas-JB rail track

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): Pestech International Bhd has bagged a RM399 million sub-contract from Syarikat Pembenaan Yeoh Tiong Lay Sdn Bhd to undertake engineering, procurement, construction and maintenance works relating to the electrification system for the electrified double track from Gemas to Johor Baru.
5219 BSMAF 1818

 
Pestech bags RM58m Sibiyu substation job

2018-08-24 theedgemarkets
KUALA LUMPUR: Pestech International Bhd’s wholly-owned subsidiary Pestech Sdn Bhd has bagged a RM57.95 million contract from Sarawak Energy Bhd’s unit Syarikat Sesco Bhd for the Sibiyu 132/33kV substation project.
5219

 
Trading ideas: Sime Plantation, Pestech, Censof

2018-08-24 thestar.com.my
KUALA LUMPUR: Sime Darby Plantation, Pestech International and Censof are among the companies which could attract trading interest on Friday, says JF Apex Research.
5219

 
Pestech bags RM58mil power job

2018-08-23 thestar.com.my
PETALING JAYA: Pestech International Bhd ‘s unit has secured a RM57.95mil contract from Sarawak Energy Bhd’s subsidary to build a substation in Bintulu.
5219 BSMAF 1818

 
Sime Darby Plantation, Axiata Group Bhd, Malakoff, Pestech, Censof, Hibiscus, S P Setia, Maybulk, MPI and Tropicana

2018-08-23 theedgemarkets
KUALA LUMPUR (Aug 23): Based on corporate announcements and news flow today, companies that will be in focus on Friday (Aug 24) may include: Sime Darby Plantation Bhd, Axiata Group Bhd, Malakoff Corp Bhd, Pestech International Bhd, Censof Holdings Bhd, Hibiscus Petroleum Bhd, S P Setia Bhd, Malaysian Bulk Carriers Bhd, Malaysian Pacific Industries Bhd and Tropicana Corp Bhd.
5347 3867 6888 TNABY 5219 5077 8664 AXXTF TNABF 5195 HIPEF 5199

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...